SCHEMBL5209985

SCHEMBL5209985

Cc1cnc(-n2ccc(C(F)(F)F)n2)nc1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.39
RAB9A P51151 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.38
RXRA P19793 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
IDH1 O75874 1/20 0.36
IDH2 P48735 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
KCNH2 Q12809 1/20 0.35
PRMT6 Q96LA8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202428 0.88 MEN1 (0.38) HSP90AA1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5205299 0.86 KIT (0.39) MAPTRXRAGRIN1GRIN2BIDH1
SCHEMBL25314609 0.84 CCR2 (0.38) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30465885 0.84 CCR2 (0.38) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30834460 0.81 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30834458 0.81 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5206965 0.77 CNR2 (0.47) RAB9ACYP1A2CYP3A4MAPTMEN1
SCHEMBL7873623 0.77 ALDH1A1 (0.44) CYP1A2CYP2C9CYP2C19MAPTMEN1
SCHEMBL5207531 0.76 RAB9A (0.46) HSP90AA1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL5207391 0.74 MPO (0.39) MAPTRXRAGRIN1GRIN2BIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1036066-B1 SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES MID AMERICA COMMERCIALIZATION (US) 2007-04-18 EP disclosed
US-20040033896-A1 E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine KOETHER GERARD (US) 2004-02-19 US disclosed
US-6525001-B1 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine MID-AMERICAN COMMERCIALIZATION CORPORATION 2003-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033896-A1 E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine PYM1, Q6ZSR9, MRM1 HSP90AA1 3881/4885RAB9A 1261/4885CYP1A2 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.